Clarithromycin-Rifampin-Based Treatment for Nontuberculous Mycobacteria Infections in Immunocompromised Patients who Require Concomitant CYP-Metabolized Medications.

Autor: Gonzalez-Bocco IH; Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Division of Infectious Disease, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Aleissa MM; Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Division of Infectious Disease, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Department of Pharmacy, Brigham and Women's Hospital, Boston, Massachusetts, USA., Zhou E; Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Division of Infectious Disease, Brigham and Women's Hospital, Boston, Massachusetts, USA., Manne-Goehler J; Division of Infectious Disease, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.; Division of Infectious Disease, Massachusetts General Hospital, Boston, Massachusetts, USA., Koo S; Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Division of Infectious Disease, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Cheng MP; Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada.; Division of Medical Microbiology, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada.; McGill Interdisciplinary Initiative in Infection and Immunity, Montreal, Quebec, Canada., Marty FM; Division of Infectious Disease, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Division of Infectious Disease, Brigham and Women's Hospital, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.
Jazyk: angličtina
Zdroj: Open forum infectious diseases [Open Forum Infect Dis] 2021 Dec 18; Vol. 9 (1), pp. ofab582. Date of Electronic Publication: 2021 Dec 18 (Print Publication: 2022).
DOI: 10.1093/ofid/ofab582
Abstrakt: Clarithromycin (CYP inhibitor) can be used instead of azithromycin for nontuberculous mycobacteria therapy in patients requiring CYP substrates to mitigate rifampin's CYP induction. We found no differences in adverse events (10/13 vs 14/17; P  = .73), drug intolerability (1/5 vs 4/11; P  = 1), or 90-day mortality (0/13 vs 1/17; P  = 1) in patients receiving clarithromycin vs azithromycin.
(© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje